In this review, Klarenbeek et al. specifically highlight antibody-based therapeutics and monoclonal antibodies (mAbs) targeting the chemokine system. Besides discussing pitfalls inherently linked to their discovery, they elaborate on where progress can be made in the development of novel human therapeutic antibodies directed at the chemokine system.